Avience Biomedicals Set for Strong Debut as GMP Indicates 62% Premium Ahead of Listing

Avience Biomedicals is poised to debut on the NSE SME platform on Thursday, with strong indications from the grey market suggesting a successful listing. The shares have been trading at a grey market premium (GMP) of approximately 62% above the issue price of Rs 208, which implies a potential listing price of around Rs 337. The IPO, amounting to Rs 30.24 crore and consisting entirely of a fresh issue of 14.54 lakh shares, has attracted significant interest, indicated by a staggering subscription rate of 385.32 times during its three-day bidding period.

The overwhelming demand was led by non-institutional investors (NII), who subscribed 597.23 times, while retail investors demonstrated robust participation at 401.36 times. Qualified Institutional Buyers (QIB) also showed a strong appetite, with bids amounting to 196.77 times the reserved shares. The fixed issue price of Rs 208 requires retail investors to apply for a minimum of 1,200 shares, totaling an investment of Rs 2.50 lakh. Avience Biomedicals specializes in molecular diagnostic solutions and plans to utilize the proceeds from the IPO to establish a new manufacturing facility, enhance working capital, and address general corporate needs.

For Indian investors, the current grey market sentiment points to optimism regarding the stock’s opening performance, although it is important to note that GMP is an unofficial metric and does not guarantee final listing outcomes. The financials reveal that Avience Biomedicals had a total income of Rs 45.97 crore and a net profit of Rs 7.23 crore for FY25. The upcoming listing is anticipated to reflect the company’s strong market positioning within the biotechnology and diagnostics sectors, potentially offering Indian investors an attractive investment opportunity as the IPO environment remains buoyant.

Source: The Economic Times

(Expert Note: This report was prepared by the Wealthova IPO team.)